Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Teva Pharmaceutical Industries Limited
< Previous
1
2
3
4
5
Next >
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
ALVO
TEVA
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
April 11, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
April 09, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
April 06, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
April 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
April 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
CG
TEVA
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
February 26, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
ALVO
TEVA
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
February 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reports Growth in Fourth Quarter and Full Year 2023
January 31, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
January 31, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
January 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
December 14, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
December 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
November 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
SNY
TEVA
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
November 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
RPRX
TEVA
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
November 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
November 07, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
November 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
November 01, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
October 25, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
October 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
October 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
October 04, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
SNY
TEVA
Teva Announces Changes to Executive Management Team
September 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.